» Articles » PMID: 22776069

Inhibition of CD200R1 Expression by C/EBP β in Reactive Microglial Cells

Overview
Publisher Biomed Central
Date 2012 Jul 11
PMID 22776069
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In physiological conditions, it is postulated that neurons control microglial reactivity through a series of inhibitory mechanisms, involving either cell contact-dependent, soluble-factor-dependent or neurotransmitter-associated pathways. In the current study, we focus on CD200R1, a microglial receptor involved in one of these cell contact-dependent mechanisms. CD200R1 activation by its ligand, CD200 (mainly expressed by neurons in the central nervous system),is postulated to inhibit the pro-inflammatory phenotype of microglial cells, while alterations in CD200-CD200R1 signalling potentiate this phenotype. Little is known about the regulation of CD200R1 expression in microglia or possible alterations in the presence of pro-inflammatory stimuli.

Methods: Murine primary microglial cultures, mixed glial cultures from wild-type and CCAAT/enhancer binding protein β (C/EBPβ)-deficient mice, and the BV2 murine cell line overexpressing C/EBPβ were used to study the involvement of C/EBPβ transcription factor in the regulation of CD200R1 expression in response to a proinflammatory stimulus (lipopolysaccharide (LPS)). Binding of C/EBPβ to the CD200R1 promoter was determined by quantitative chromatin immunoprecipitation (qChIP). The involvement of histone deacetylase 1 in the control of CD200R1 expression by C/EBPβ was also determined by co-immunoprecipitation and qChIP.

Results: LPS treatment induced a decrease in CD200R1 mRNA and protein expression in microglial cells, an effect that was not observed in the absence of C/EBPβ. C/EBPβ overexpression in BV2 cells resulted in a decrease in basal CD200R1 mRNA and protein expression. In addition, C/EBPβ binding to the CD200R1 promoter was observed in LPS-treated but not in control glial cells, and also in control BV2 cells overexpressing C/EBPβ. Finally, we observed that histone deacetylase 1 co-immunoprecipitated with C/EBPβ and showed binding to a C/EBPβ consensus sequence of the CD200R1 promoter in LPS-treated glial cells. Moreover, histone deacetylase 1 inhibitors reversed the decrease in CD200R1 expression induced by LPS treatment.

Conclusions: CD200R1 expression decreases in microglial cells in the presence of a pro-inflammatory stimulus, an effect that is regulated, at least in part, by C/EBPβ. Histone deacetylase 1 may mediate C/EBPβ inhibition of CD200R1 expression, through a direct effect on C/EBPβ transcriptional activity and/or on chromatin structure.

Citing Articles

The regulation of NFKB1 on CD200R1 expression and their potential roles in Parkinson's disease.

Lin S, Shu Y, Shen R, Zhou Y, Pan H, He L J Neuroinflammation. 2024; 21(1):229.

PMID: 39294682 PMC: 11409543. DOI: 10.1186/s12974-024-03231-3.


C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease.

Yao Q, Long C, Yi P, Zhang G, Wan W, Rao X CNS Neurosci Ther. 2024; 30(4):e14721.

PMID: 38644578 PMC: 11033503. DOI: 10.1111/cns.14721.


C/EBPβ Regulates TFAM Expression, Mitochondrial Function and Autophagy in Cellular Models of Parkinson's Disease.

Sierra-Magro A, Bartolome F, Lozano-Munoz D, Alarcon-Gil J, Gine E, Sanz-SanCristobal M Int J Mol Sci. 2023; 24(2).

PMID: 36674978 PMC: 9865173. DOI: 10.3390/ijms24021459.


Mechanically Activated Calcium Channel PIEZO1 Modulates Radiation-Induced Epithelial-Mesenchymal Transition by Forming a Positive Feedback With TGF-β1.

Huang J, Zhang H, Guo X, Lu Y, Wang S, Cheng B Front Mol Biosci. 2021; 8:725275.

PMID: 34722630 PMC: 8548710. DOI: 10.3389/fmolb.2021.725275.


Microglia at the Centre of Brain Research: Accomplishments and Challenges for the Future.

Soares N, Vieira H Neurochem Res. 2021; 47(2):218-233.

PMID: 34586585 DOI: 10.1007/s11064-021-03456-1.


References
1.
Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D . Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 1995; 14(9):1932-41. PMC: 398292. DOI: 10.1002/j.1460-2075.1995.tb07185.x. View

2.
Liu Y, Chen C, Tseng H, Chang W . Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages. Cell Signal. 2006; 18(9):1492-500. DOI: 10.1016/j.cellsig.2005.12.001. View

3.
Kapadia R, Tureyen K, Bowen K, Kalluri H, Johnson P, Vemuganti R . Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein beta knockout mice following transient focal cerebral ischemia. J Neurochem. 2006; 98(6):1718-31. DOI: 10.1111/j.1471-4159.2006.04056.x. View

4.
Brenner S, Prosch S, Schenke-Layland K, Riese U, Gausmann U, Platzer C . cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J Biol Chem. 2002; 278(8):5597-604. DOI: 10.1074/jbc.M207448200. View

5.
Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury S, Huang T . CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci. 2010; 30(6):2025-38. PMC: 2837938. DOI: 10.1523/JNEUROSCI.4272-09.2010. View